Neuropsychiatric Disorders and Treatment: News Highlights
Here's a summary of recent news and advancements in the field of neuropsychiatric disorders and their treatment:
As per MRFR analysis, the Neuropsychiatric Disorders and Treatment Market Size was estimated at 145.03 (USD Billion) in 2024. The Neuropsychiatric Disorders and Treatment Market Industry is expected to grow from 159.82 (USD Billion) in 2025 to 383.13 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 10.20% during the forecast period (2025 - 2034).
Novel Treatment Approaches & Clinical Trials:
Photobiomodulation (PBM) for Treatment-Resistant Disorders: The Brain Photobiomodulation Clinic at Massachusetts General Hospital is offering transcranial PBM as a non-invasive treatment for conditions like major depressive disorder, generalized anxiety disorder, traumatic brain injury, and Alzheimer's disease. PBM uses near-infrared light to stimulate neurons, promoting beneficial effects like reduced inflammation and improved neuroplasticity.
Neuroplastogen Development: Transneural Therapeutics is developing novel neuroplastogens, including TN-001, which aims to provide rapid and sustained antidepressant effects similar to psychedelics but without the hallucinatory side effects. TN-001 is currently in preclinical development for major depressive disorder and PTSD.
AI-Powered Personalized Brain Stimulation: Researchers at NIMHANS in Bengaluru, India, have developed AI-powered software to personalize transcranial direct current stimulation (tDCS) for neuropsychiatric disorders like dementia and depression. The software calculates individualized treatment parameters based on brain scans, and preliminary results show significant benefits in dementia patients.
LB-102 for Schizophrenia: LB Pharmaceuticals announced positive Phase 2 results for LB-102 (N-methyl amisulpride), a novel dopamine D2/3/5-HT7 inhibitor, in treating acute schizophrenia. The drug demonstrated significant efficacy in reducing symptoms with a favorable safety profile.
Osavampator for Major Depressive Disorder: Neurocrine Biosciences has initiated a Phase 3 trial to evaluate osavampator as an adjunctive treatment for major depressive disorder.
Gene Therapy for Neuropsychiatric Disorders: Professor Gabriele Lignani at UCL is leading an international team to develop cell-state gene therapies for disorders like epilepsy, schizophrenia, and dementia. This approach uses viral vectors activated by ultrasound to precisely target affected brain areas.
Advancements in Understanding and Diagnosis:
Dopamine's Role in Cognitive Flexibility Confirmed: PET imaging has confirmed a direct neurobiochemical link between dopamine and cognitive flexibility, providing a deeper understanding of brain function relevant to various neuropsychiatric conditions.
Genetic Risk for Schizophrenia Linked to Placenta: An international study identified associations between modifications in the placenta and the risk of developing schizophrenia, bipolar disorder, and major depression, 1 highlighting the importance of early developmental factors. www.sciencedaily.com
AI for Biomarker Discovery: Arrivo BioVentures is utilizing AI combined with qEEG technology to understand the target engagement and dose response of their SIRT6 activator for major depressive disorder, potentially identifying other targetable diseases.
Blood Test for Alzheimer's Disease: Spear Bio received FDA Breakthrough Device Designation for its pTau 217 blood test, offering a less invasive alternative for Alzheimer's diagnosis and differentiation from other neurodegenerative disorders.
Other Key Developments:
First AI Therapy Chatbot Trial Shows Promise: A clinical trial of an AI-powered therapy chatbot demonstrated clinically significant improvements in individuals with diagnosed mental disorders, suggesting a potential new avenue for accessible mental health care.
Deep Brain Stimulation (DBS) Clinical Trial Best Practices: Researchers have outlined key practices for conducting ethical and scientifically rigorous clinical trials for DBS in neuropsychiatric disorders, emphasizing the need for careful consideration of the vulnerable patient population and the complexity of the treatment.
Expanded Esketamine Nasal Spray Approval: The FDA approved a supplemental New Drug Application for esketamine (Spravato) nasal spray as the first monotherapy for adults with treatment-resistant depression.
These news highlights reflect the dynamic and rapidly evolving landscape of neuropsychiatric research and treatment, with a focus on innovative therapies, improved diagnostic tools, and a deeper understanding of the biological underpinnings of these complex conditions.